Welcome to the e-CCO Library Archive!

Filter:
P432. Tumor necrosis factor-α antagonists and malignancy in inflammatory bowel disease
P432

Do tumor necrosis factor alpha antagonists reduce the development of advanced colonic neoplasia?

Authors:

D.Y. Oh*1, J.Y. Lee2, S.-J. Koh1, H. Yoon3, Y.S. Park3, H.W. Kang4, J.P. Im2, J.W. Kim1, B.G. Kim1, J.S. Kim2, K.L. Lee1

1Department of Internal Medicine, Seoul National University Boramae Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of, 2Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of, 3Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of, 4Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Korea, Republic of

P433.

Is e-Health, web-based monitoring and treatment, useful for children and adolescents with inflammatory bowel disease? – a paediatric clinical trial

Authors:

K. Carlsen1,2, C. Jakobsen1, L.F. Hansen1, A. Paerregaard1, V. Wewer1, P. Munkholm2, 1Copenhagen University Hospital, Department of Paediatrics, Hvidovre, Denmark, 2Copenhagen University Hospital, Department of Gastroenterology, Herlev, Denmark

P433. High incidence of colorectal cancer in Finnish patients with concomitant inflammatory bowel disease and primary sclerosing cholangitis
P433. Mercaptopurine therapy in IBD patients modulates GTPase Rac1
Authors:

M. Seinen1, G. van Nieuw amerongen2, N. de Boer1, J. van Bezu2, C. Mulder1, A. van Bodegraven1, 1VU University medical center, Gastroenterology and Hepatology, Amsterdam, Netherlands, 2VU University medical center, Physiology, Amsterdam, Netherlands

P433

Efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with ulcerative colitis from GEMINI 1

Authors:

J.-F. Colombel*1, E.V. Loftus Jr2, C.A. Siegel3, J.D. Lewis4, M. Smyth5, S. Sankoh6, B. Abhyankar7

1Icahn School of Medicine at Mount Sinai Hospital, Gastroenterology, New York, NY, United States, 2Mayo Clinic, Gastroenterology and Hepatology, Rochester, Minnesota, United States, 3Dartmouth-Hitchcock Medical Center, Gastroenterology and Hepatology, Hanover, New Hampshire, United States, 4University of Pennsylvania Perelman School of Medicine, Gastroenterology, Philadelphia, Pennsylvania, United States, 5Takeda Global Research and Development Centre (Europe) Ltd., Medical, London, United Kingdom, 6Takeda Pharmaceuticals International Co., Statistics, Cambridge, Massachusetts, United States, 7Takeda Global Research and Development Centre (Europe) Ltd., Clinical Science, London, United Kingdom

P434.

Iron deficiency anemia in inflammatory bowel disease: are we treating our patients efficiently?

Authors:

D. Trabulo, C. Teixeira, J. Mangualde, I. Cremers, A.P. Oliveira, Centro Hospitalar de Setúbal – Hospital de São Bernardo, Gastroenterology, Setúbal, Portugal

P434. IBD patients have a higher rate of femoral neck fractures: A record-linkage study of English hospital admissions from 1999–2008
P434. Medical resource utilization and associated costs in patients with ulcerative colitis in the UK: A chart review analysis
Authors:

K. Bodger1, L. Yen2, A. Szende3, J. McDermott4, P. Hodgkins2, 1Digestive Diseases Centre, Aintree University Hospital, Liverpool, United Kingdom, 2Shire Development LLC, Wayne, PA, United States, 3Covance, Leeds, United Kingdom, 4Covance, Gaithersburg, MD, United States

P434

Clinical utility of routine measurement of Anti-TNF levels and their antibodies in inflammatory bowel disease (IBD)

Authors:

S. Sarwar*, K. Foster, E. Corn, S. Moss

Diana Princes of Wales Hospital , Gastroenterology, Grimsby, United Kingdom

P435.

Intravenous iron need to maintain stable haemoglobin – an open-label, 1 year extension study of iron isomaltoside 1000 in subjects with inflammatory bowel disease

Authors:

W. Reinisch, on behalf of the study group, Medical University Hospital, Department of Internal Medicine III, Vienna, Austria

P435. Malignancies and cancer mortality in patients with ulcerative colitis; a nationwide study in Finland
P435. Management of iron deficiency in inflammatory bowel disease: results from a RAND/UCLA appropriateness study
Authors:

W. Reinisch1, Y. Chowers2, S. Danese3, A. Dignass4, F. Gomollón5, O. Haagen Nielsen6, P. Lakatos7, C. Lees8, S. Lindgren9, M. Lukas10, G. Mantzaris11, P. Michetti12, B. Moum13, L. Peyrin Biroulet14, M. Toruner15, C.J. van der Woude16, G. Weiss17, H. Stoevelaar18, 1Medical University of Vienna, Department Internal Medicine III, Vienna, Austria, 2Rambam Medical Center, Department of Gastroenterology, Haifa, Israel, 3Humanitas Clinical and Research Center, Department of Gastroenterology, Milan, Italy, 4Agaplesion Markus Hospital, Department of Gastroenterology, Oncology, Infectious Diseases and Metabolism, Frankfurt, Germany, 5Hospital Clínico Universitario, CIBEREHD, Zaragoza, Spain, 6Herlev Hospital, University of Copenhagen, Department of Gastroenterology, Copenhagen, Denmark, 7Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 8Western General Hospital, Department of Gastroenterology, Edinburgh, United Kingdom, 9University of Lund, University Hospital Skane, Department of Gastroenterology, Malmö, Sweden, 10Charles University, IBD Clinical and Reasearch Centre, ISCARE Lighthouse and 1st Medical Faculty, Prague, Czech Republic, 11Evangelismos Hospital, Department of Gastroenterology, Athens, Greece, 12Lausanne University Medical Center, Department of Gastroenterology, Lausanne, Switzerland, 13Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 14University Hospital of Nancy, Université Henri Poincaré 1, Inserm, U954 and Department of Hepato-Gastroenterology, Vandoeuvre-lès-Nancy, France, 15Ankara University School of Medicine, Department of Gastroenterology, Ankara, Turkey, 16Erasmus University Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, 17Medical University of Innsbruck, Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Innsbruck, Austria, 18Ismar Healthcare, Center for Decision Analysis and Support, Lier, Belgium

P435

Maintenance of Remission with Partial Enteral Nutrition Therapy in pediatric Crohn's Disease: A retrospective study.

Authors:

J. Schulman, R. Shaoul*

Rambam Medical Center, Pediatric Gastroenterology, Haifa, Israel

P436.

Intravenous cyclophosphamide combined with thalidomide has a promising effect in refractory Crohn's disease

Authors:

J. Tang, X. Gao, M. Zhi, H. Zhou, M. Zhang, H. Chen, Q. Yang, Z. Liang, The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China

P436. Clinical course of ulcerative colitis according to the partial Mayo score based classification during two-year follow-up period: Result from a Hungarian multicenter IBD database
P436. Malignancies in children receiving infliximab and other inflammatory bowel disease therapies: an inflammatory bowel disease multicenter, prospective, long-term registry of pediatric patients (DEVELOP) registry data
Authors:

R. Colletti1, S. Cucchiara2, M. Dubinsky3, J. Escher4, W. Faubion5, J. Fell6, B. Gold7, A. Griffiths8, J. Hyams9, S. Koletzko10, S. Kugathasan11, H. Winter12, R. Baldassano13, J. Markowitz14, F.M. Ruemmele15, P. Callegari16, M. Molenda16, L. Tang16, R. Wright16, G. Veereman17, 1University of Vermont, United States, 2University of Rome, Italy, 3Cedars-Sinai Medical Center, United States, 4Erasmus MC-Sophia Children's Hospital, Netherlands, 5Mayo Clinic, United States, 6Chelsea and Westminster Hospital, United Kingdom, 7Children's Center for Digestive Healthcare Pediatric Gastroenterology, United States, 8Hospital for Sick Children, Canada, 9Connecticut Children's Medical Center, United States, 10Ludwig Maximilians University, Germany, 11Emory University School of Medicine, United States, 12MassGeneral Hospital for Children, United States, 13Children's Hospital of Philadelphia, United States, 14Cohen Children's Medical Center of New York, United States, 15Hôpital Necker-Enfants Malades, France, 16Janssen Services, LLC, United States, 17KCE-Belgian Health Care Knowledge Centre, Belgium

P436

Efficacy and safety of azathioprine treatment in Asian patients with Ulcerative Colitis

Authors:

R. Mao*1, Y.-f. Li2, B.-l. Chen1, Y. He1, Z.-r. Zeng1, M.-h. Chen1

1First Affiliated Hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, China, 2Singapore General Hospital, Department of Internal Medicine, Singapore, Singapore

P437.

Intravenous (IV) ferumoxytol (FER) for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD): Efficacy, safety and health-related quality of life (HRQOL)

Authors:

D. Hetzel1, D. Ford2, N. Dahl3, W. Strauss3, 1Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia, 2Toronto Digestive Disease Associates, Inc, Gastroenterology, Vaughan, Ontario, Canada, 3AMAG Pharmaceuticals, Inc, Medical Affairs, Waltham, MA, United States

P437. Maintaining remission in ulcerative colitis: 5-aminosalicylic acid (5-ASA) therapy
Authors:

S. Din1, J. O'Kelly1, I. Arnott1, 1NHS Lothian, GI Unit, Edinburgh, United Kingdom